India Said to Block Fosun's $1.3B Gland Takeover

The video discusses the acquisition strategies of Chinese pharmaceutical companies, focusing on their global expansion and interest in the US market. It highlights India's potential rejection of a deal due to geopolitical tensions, particularly the renewed border disputes with China. The changing investment climate in China, with less encouragement for overseas investments, is also examined, alongside India's cautious approach to Chinese investments.

What is considered the 'Holy Grail' for companies looking to expand internationally?

What impact has the renewed border spat between China and India had on investments?